Reconnecting

The current page stays visible while onset.to reconnects in the background.

Connection error

onset.to could not restore the live connection within 5 seconds. Reload the page to recover.

Log in

Psilocybin

Psilocybin content spanning clinical trials, mushroom science, public policy, and community discussion around one of the core substances in the psychedelic resurgence.

Most recent Latest added

Most recent Latest added

391 entries

August 5, 2026

Psilocybin could help kick-start anorexia recovery as early clinical results suggest improved flexibility, emotional processing and openness to change

scientificamerican.com · Aug 5, 2026 · Alexandra Pattillo

Psilocybin Article Clinical Research Therapy

August 1, 2026

Occasional psilocybin use among alcohol drinkers is linked to better mental health, with lower depression and stress in a large U.S. survey sample

psypost.org · Aug 1, 2026 · Eric W. Dolan

Psilocybin Cannabis Article Clinical Research

July 30, 2026

Psilocybin trial for military veterans with PTSD highlights clinical interest in psychedelic-assisted treatment and the challenges of study design and access

psychedelicstoday.com · Jul 30, 2026 · Psychedelics Today

Psilocybin Clinical Research Therapy

Psilocybin-assisted therapy shows promise for veterans with severe treatment-resistant PTSD in a small open-label pilot study with notable symptom reductions

psypost.org · Jul 30, 2026 · Eric W. Dolan

Psilocybin Clinical Research Therapy

July 26, 2026

Psychedelics may influence inflammation, metabolism, immunity, and aging pathways beyond mental health through serotonin signaling and neuroimmune effects

thesporereport.com · Jul 26, 2026 · admin

LSD Psilocybin Article Clinical +5

July 25, 2026

Expectancy bias in psychedelic trials can inflate reported benefits by shaping participant experiences, blinding failure, and the interpretation of outcomes in psilocybin research

thesporereport.com · Jul 25, 2026 · admin

Psilocybin Article Clinical Research Therapy

July 24, 2026

The Psychedelic Inflection Point: Big Pharma, FDA, and the Next Wave of Brain Medicines

youtube.com · Jul 24, 2026 · Tim Gortman

Psilocybin DMT Podcast Business +4

July 22, 2026

Psychedelics enter mainstream cancer care discussions as clinicians examine distress relief, end-of-life anxiety, and the evidence needed for safe adoption

cancerletter.com · Jul 22, 2026

Psilocybin MDMA Podcast Clinical +3

July 21, 2026

Q3 2026 psychedelic drug development pipeline bullseye charts map clinical-stage programs, company momentum, and the concentration of targets across indications

psychedelicalpha.com · Jul 21, 2026

LSD Psilocybin Clinical Industry +7

A Once-in-a-Century Shift in Mental Health | Trade to Black

youtube.com · Jul 21, 2026 · Shadd Dales

LSD Psilocybin Interview Clinical +3

July 20, 2026

"Journeys" follows psilocybin therapy through personal healing stories and clinical context, highlighting preparation, guided sessions, and integration in mental health care

psychedelicstoday.com · Jul 20, 2026 · Psychedelics Today

Psilocybin Clinical Mainstream Therapy

Psilocybin on the Verge: Treating Depression at Compass Pathways

youtube.com · Jul 20, 2026 · Dr. Steve Levine

Psilocybin Ketamine Interview Clinical +2

July 19, 2026

New study links psilocybin-assisted therapy to lasting reductions in depression symptoms and changes in brain network flexibility over several months

sciencedaily.com · Jul 19, 2026

Psilocybin Clinical Research Therapy

July 17, 2026

Psilocybin research is being considered for Alzheimer's disease as scientists examine neuroplasticity, inflammation, and cognition in relation to magic mushrooms

thesporereport.com · Jul 17, 2026 · admin

Psilocybin Article Clinical Research

July 16, 2026

Psychedelics and adult ADHD draw rising interest, but current evidence remains limited, mixed, and far from establishing a safe or effective treatment approach

thesporereport.com · Jul 16, 2026 · admin

LSD Psilocybin Article Clinical +4

Compass Pathways reports a post-hoc analysis saying COMP360 trial monitoring and support are distinct from psychotherapy in psilocybin treatment research

ir.compasspathways.com · Jul 16, 2026

Psilocybin Clinical Industry Research

July 14, 2026

Psilocybin therapy for depression faces unresolved FDA, reimbursement, training, and delivery risks even after COMPASS reports two positive phase 3 results

clinicaltrialvanguard.com · Jul 14, 2026 · Moe Alsumidaie

Psilocybin Clinical Industry Policy

July 13, 2026

FDA issues final guidance for psychedelic drug development and schedules a September public hearing on the future of psychedelic therapies

psychedelicalpha.com · Jul 13, 2026

Psilocybin MDMA Clinical Policy Therapy

July 10, 2026

Luvelsilocin enters FDA trials as a fast-acting psilocybin-derived treatment candidate for postpartum depression with effects designed to fit a short therapeutic window

psypost.org · Jul 10, 2026 · Camille Hoffman

Psilocybin Article Clinical Research Therapy

July 9, 2026

Entropy Neurodynamics Webinar: Landmark results in treatment-resistant Binge Eating Disorder

youtube.com · Jul 9, 2026 · Jason Carroll

Psilocybin Video Clinical Research Therapy

July 8, 2026

Cascades Analytics with Tanya Ramey (Altaïr, Former Usona, Pfizer, NIDA)

youtube.com · Jul 8, 2026 · Cascades Analytics

Psilocybin 5-MeO-DMT Interview Clinical +3

Pilot study makes a strong early case for psilocybin as a treatment for anorexia nervosa, with notable symptom improvement and acceptable safety signals

thesporereport.com · Jul 8, 2026 · admin

Psilocybin Article Clinical Research Therapy

Psilocybin therapy for adult females with anorexia nervosa: pilot study in The British Journal of Psychiatry assessing feasibility, safety and early clinical signals

cambridge.org · Jul 8, 2026

Psilocybin Clinical Research Therapy

July 7, 2026

Compass Pathways reports six-month results from its second Phase 3 trial, saying psilocybin treatment produced rapid and durable effects in treatment-resistant depression

ir.compasspathways.com · Jul 7, 2026

Psilocybin Clinical Industry Research

July 5, 2026

Classic psychedelics are linked to lasting increases in openness and reductions in neuroticism, with effects shaped by mystical experiences and ego dissolution

psypost.org · Jul 5, 2026 · Eric W. Dolan

LSD Psilocybin Article Clinical +5